Practice Essentials

The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma
The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma
CME, CPE
Stephen M. Ansell, MD, PhD
Release Date: October 19, 2017
Expiration Date: October 19, 2018
There are a number of investigational therapies and drug combinations being studied in the frontline treatment of patients with Hodgkin lymphoma (HL), including brentuximab vedotin (BV) in combination with immunotherapy, namely nivolumab, or various chemotherapy regimens. Health care providers must be aware of the potential impact of these new therapies on existing treatment paradigms and the standard of care in newly diagnosed HL. In this activity, participants will learn about the various investigational therapies and treatment strategies being studied in the frontline treatment of HL, as well as hear from expert faculty on the interpretation of the data and its relevance for clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
 Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
CME, CPE
John Sweetenham, MD, FRCP, FACP
Release Date: August 23, 2017
Expiration Date: August 23, 2018
In this activity, participants will learn about treatment strategies and algorithms for selecting therapy in patients with relapsed and refractory Hodgkin lymphoma from Dr. John Sweetenham, who will also address the role of patient- and disease-related factors in treatment decisions, such as preexisting comorbidities, tolerability, and response to prior therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma
Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma
CME, CPE
Craig Moskowitz, MD
Release Date: May 19, 2017
Expiration Date: May 19, 2018
The approval of nivolumab in May of 2016 for patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after autologous stem cell transplant and post-transplantation brentuximab vedotin, represented the first checkpoint inhibitor in HL. The unique features of checkpoint inhibitors, including immune-mediated adverse events and the possibility of non-traditional response patterns, may create a challenge in using these agents in practice. In this activity, Dr. Moskowitz will discuss the clinical profiles of recently approved immunotherapeutic agents, as they relate to HL, focusing on practical strategies for treatment and management of patients in practice, as well as on the safety and efficacy profiles of each.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved